C12N 2760/00062
By genetic engineering
Official title: by genetic engineering
C12N2760/00062 (By genetic engineering) appears on 8 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 12
- Assignees
- 11
- Inventors
- 16
- Latest grant
- 6 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 2 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 2 | 3 |
| 2019 | 1 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 2 | 2 |
| 2023 | 0 | 0 |
| 2024 | 2 | 2 |
By publication year.
Recent patents
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes6 Aug 2024US 12,054,519 B2Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization6 Aug 2024US 12,054,749 B2The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes19 Jul 2022US 11,390,651 B2Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization28 Jun 2022US 11,371,024 B2The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes20 Oct 2020US 10,808,012 B2Codagenix Inc.
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes19 Dec 2024US 2024/0417431 A1Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization19 Dec 2024US 2024/0417699 A1The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes27 Oct 2022US 2022/0340619 A1Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization13 Oct 2022US 2022/0325252 A1The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes24 Jun 2021US 2021/0188920 A1Codagenix Inc.
Most cited
By later US patents
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization7US 9,957,486 B2The Research Foundation for The State University of New York · 2018
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes4US 10,808,012 B2Codagenix Inc. · 2020
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization2US 11,371,024 B2The Research Foundation for The State University of New York · 2022
- Attenuated influenza vaccines and uses thereof1US 9,878,032 B2University of Rochester · 2018